細菌性肺炎の世界市場レポート 2025年

細菌性肺炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で35億1,000万米ドルに成長します。予測期間における成長の原動力は、タバコやアルコール消費の増加、政府の取り組みや助成金の増加、呼吸器感染症の有病率の増加、抗生物質耐性の上昇、医療アクセスの拡大、細菌性肺炎の認知度向上、新規治療薬やワクチンの進歩などです。主な動向としては、革新的な抗生物質の開発、迅速診断ツールの採用、ワクチン技術の進歩、個別化医療の出現、疾病管理におけるAIの統合、モノクローナル抗体の使用拡大などが挙げられます。

呼吸器疾患の有病率の増加は、細菌性肺炎市場の成長を促進すると予想されます。呼吸器疾患は、肺や気道系の臓器や組織に影響を及ぼすことで呼吸やガス交換を阻害する病状を包含します。呼吸器疾患の罹患率上昇には、環境、ライフスタイル、人口動態、遺伝的影響など、いくつかの要因が関与しています。このような状況は、免疫系を弱め、肺組織を損傷することにより、細菌感染に好都合な環境を作り出し、細菌性肺炎に対する感受性を高める。例えば、2024年3月、米国の政府機関である疾病対策予防センターは、結核患者数が2022年の8,320人から2023年には9,615人と1,295人増加したと報告しました。その結果、呼吸器疾患の有病率の増加が細菌性肺炎市場の拡大に拍車をかけています。

細菌性肺炎市場の主要企業は、免疫反応を高め、有効性を向上させ、複数の細菌株に対する幅広い保護を提供するために、結合型ワクチンの開発など、ワクチン技術の革新を重視しています。コンジュゲート・ワクチンは、弱い抗原をキャリア・タンパク質に結合させることで、免疫力を効果的に高める。例えば、2024年6月にMerck &Co.Inc.は、米国食品医薬品局（FDA）からCAPVAXIVE（肺炎球菌21価結合型ワクチン）の承認を取得しました。このワクチンは、肺炎球菌の様々な血清型によって引き起こされる侵襲性肺炎球菌感染症および肺炎を予防するためのもので、特に18歳以上の成人を対象としています。このワクチンの導入は、細菌性肺炎および関連する肺炎球菌感染症と闘う上で極めて重要な役割を果たします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界細菌性肺炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の細菌性肺炎市場：成長率分析
• 世界の細菌性肺炎市場の実績：規模と成長, 2019-2024
• 世界の細菌性肺炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界細菌性肺炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の細菌性肺炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市中肺炎（CAP）
• 院内肺炎（HAP）
• 世界の細菌性肺炎市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 皮下
• その他の投与経路
• 世界の細菌性肺炎市場治療法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ワクチン
• 薬物
• 世界の細菌性肺炎市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の細菌性肺炎市場市中肺炎（CAP）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎球菌
• インフルエンザ菌
• マイコプラズマ肺炎
• クラミジア肺炎
• レジオネラ・ニューモフィラ
• 世界の細菌性肺炎市場院内肺炎（HAP）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 緑膿菌
• 黄色ブドウ球菌
• クレブシエラ・ニューモニエ
• アシネトバクター・バウマニ
• エンテロバクター属

第7章 地域別・国別分析

• 世界の細菌性肺炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の細菌性肺炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 細菌性肺炎市場：競合情勢
• 細菌性肺炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GSK plc
• bioMerieux SA
• Shionogi & Co. Ltd.
• Wockhardt Limited.
• Zai Lab Limited
• Innoviva Inc.
• Eagle Pharmaceuticals Inc.
• Basilea Pharmaceutica Ltd.
• Paratek Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Melinta Therapeutics Inc.
• Nabriva Therapeutics plc.
• Clarametyx Biosciences Inc.
• Evopoint Biosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 細菌性肺炎市場2029：新たな機会を提供する国
• 細菌性肺炎市場2029：新たな機会を提供するセグメント
• 細菌性肺炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Bacterial pneumonia is a severe and potentially life-threatening respiratory condition caused by bacterial infections. It leads to inflammation and the accumulation of fluid or pus in the alveoli of the lungs, which disrupts normal oxygen exchange. This results in symptoms such as a severe cough, difficulty breathing, fever, chills, and chest pain, necessitating prompt medical intervention and appropriate treatment.

The primary types of bacterial pneumonia include community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Community-acquired pneumonia (CAP) is a lung infection that develops outside healthcare settings and is typically caused by bacteria, viruses, or fungi, leading to lung inflammation and impaired gas exchange. Treatments are administered through oral, subcutaneous, or other methods and include vaccines and medications. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The bacterial pneumonia market research report is one of a series of new reports from The Business Research Company that provides bacterial pneumonia market statistics, including the bacterial pneumonia industry's global market size, regional shares, competitors with a bacterial pneumonia market share, detailed bacterial pneumonia market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial pneumonia industry. This bacterial pneumonia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bacterial pneumonia market size has grown strongly in recent years. It will grow from $2.31 billion in 2024 to $2.52 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to increased awareness of respiratory diseases, a higher prevalence of bacterial infections, a growing geriatric population, increased healthcare expenditure, rapid urbanization, and rising air pollution levels.

The bacterial pneumonia market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is driven by rising tobacco and alcohol consumption, increased government initiatives and funding, a growing prevalence of respiratory infections, rising antibiotic resistance, expanded healthcare access, greater awareness of bacterial pneumonia, and advancements in novel therapeutics and vaccines. Key trends include the development of innovative antibiotics, adoption of rapid diagnostic tools, advancements in vaccine technology, emergence of personalized medicine, integration of AI in disease management, and expanded use of monoclonal antibodies.

The increasing prevalence of respiratory diseases is anticipated to drive the growth of the bacterial pneumonia market. Respiratory diseases encompass medical conditions that disrupt breathing and gas exchange by affecting the organs and tissues of the lungs and airway systems. Several factors contribute to the rising incidence of respiratory diseases, including environmental, lifestyle, demographic, and genetic influences. These conditions heighten susceptibility to bacterial pneumonia by weakening the immune system and damaging lung tissues, thereby creating a favorable environment for bacterial infections. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported an increase in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Consequently, the growing prevalence of respiratory diseases is fueling the expansion of the bacterial pneumonia market.

Leading companies in the bacterial pneumonia market are emphasizing innovations in vaccine technology, such as the development of conjugate vaccines, to enhance immune response, improve efficacy, and offer broader protection against multiple bacterial strains. Conjugate vaccines work by linking a weak antigen to a carrier protein to effectively boost immunity. For instance, in June 2024, Merck & Co. Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). This vaccine is designed to prevent invasive pneumococcal disease and pneumonia caused by various serotypes of Streptococcus pneumoniae, specifically targeting adults aged 18 and older. The introduction of this vaccine plays a crucial role in combating bacterial pneumonia and related pneumococcal infections.

In August 2022, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for $2.1 billion. Through this acquisition, GSK aims to strengthen its vaccine research and development by leveraging Affinivax's MAPS technology to create next-generation pneumococcal vaccines with expanded coverage and enhanced immunity. This advancement seeks to address unmet needs in bacterial pneumonia prevention. Affinivax Inc. is a US-based biotechnology company specializing in the development of vaccines for respiratory conditions.

Major players in the bacterial pneumonia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, GSK plc, bioMerieux SA, Shionogi & Co. Ltd., Wockhardt Limited., Zai Lab Limited, Innoviva Inc., Eagle Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc., Clarametyx Biosciences Inc., Evopoint Biosciences Inc., Vaxcyte Inc., and Acurx Pharmaceuticals Inc.

North America was the largest region in the bacterial pneumonia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bacterial pneumonia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bacterial pneumonia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bacterial pneumonia market includes revenues earned by entities by providing services such as chest X-rays and computed tomography (CT) scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial pneumonia market consists of sales of broad-spectrum antibiotics, narrow-spectrum antibiotics, pneumococcal vaccines, mechanical ventilators, cough suppressants, and expectorants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bacterial Pneumonia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bacterial pneumonia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bacterial pneumonia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bacterial pneumonia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Community-Acquired Pneumonia (CAP); Hospital-Acquired Pneumonia (HAP)
• 2) By Route Of Administration: Oral; Subcutaneous; Other Route Of Administration
• 3) By Treatments: Vaccines; Drugs
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Community-Acquired Pneumonia (CAP): Streptococcus pneumoniae; Haemophilus influenzae; Mycoplasma pneumoniae; Chlamydia pneumoniae; Legionella pneumophila
• 2) By Hospital-Acquired Pneumonia (HAP): Pseudomonas aeruginosa; Staphylococcus aureus; Klebsiella pneumoniae; Acinetobacter baumannii; Enterobacter spp
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bacterial Pneumonia Market Characteristics

3. Bacterial Pneumonia Market Trends And Strategies

4. Bacterial Pneumonia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Bacterial Pneumonia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bacterial Pneumonia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bacterial Pneumonia Market Growth Rate Analysis
• 5.4. Global Bacterial Pneumonia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bacterial Pneumonia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bacterial Pneumonia Total Addressable Market (TAM)

6. Bacterial Pneumonia Market Segmentation

• 6.1. Global Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)
• 6.2. Global Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous
• Other Route Of Administration
• 6.3. Global Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Drugs
• 6.4. Global Bacterial Pneumonia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Bacterial Pneumonia Market, Sub-Segmentation Of Community-Acquired Pneumonia (CAP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Streptococcus pneumoniae
• Haemophilus influenzae
• Mycoplasma pneumoniae
• Chlamydia pneumoniae
• Legionella pneumophila
• 6.6. Global Bacterial Pneumonia Market, Sub-Segmentation Of Hospital-Acquired Pneumonia (HAP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pseudomonas aeruginosa
• Staphylococcus aureus
• Klebsiella pneumoniae
• Acinetobacter baumannii
• Enterobacter spp

7. Bacterial Pneumonia Market Regional And Country Analysis

• 7.1. Global Bacterial Pneumonia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bacterial Pneumonia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bacterial Pneumonia Market

• 8.1. Asia-Pacific Bacterial Pneumonia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bacterial Pneumonia Market

• 9.1. China Bacterial Pneumonia Market Overview
• 9.2. China Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bacterial Pneumonia Market

• 10.1. India Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bacterial Pneumonia Market

• 11.1. Japan Bacterial Pneumonia Market Overview
• 11.2. Japan Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bacterial Pneumonia Market

• 12.1. Australia Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bacterial Pneumonia Market

• 13.1. Indonesia Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bacterial Pneumonia Market

• 14.1. South Korea Bacterial Pneumonia Market Overview
• 14.2. South Korea Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bacterial Pneumonia Market

• 15.1. Western Europe Bacterial Pneumonia Market Overview
• 15.2. Western Europe Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bacterial Pneumonia Market

• 16.1. UK Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bacterial Pneumonia Market

• 17.1. Germany Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bacterial Pneumonia Market

• 18.1. France Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bacterial Pneumonia Market

• 19.1. Italy Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bacterial Pneumonia Market

• 20.1. Spain Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bacterial Pneumonia Market

• 21.1. Eastern Europe Bacterial Pneumonia Market Overview
• 21.2. Eastern Europe Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bacterial Pneumonia Market

• 22.1. Russia Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bacterial Pneumonia Market

• 23.1. North America Bacterial Pneumonia Market Overview
• 23.2. North America Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bacterial Pneumonia Market

• 24.1. USA Bacterial Pneumonia Market Overview
• 24.2. USA Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bacterial Pneumonia Market

• 25.1. Canada Bacterial Pneumonia Market Overview
• 25.2. Canada Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bacterial Pneumonia Market

• 26.1. South America Bacterial Pneumonia Market Overview
• 26.2. South America Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bacterial Pneumonia Market

• 27.1. Brazil Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bacterial Pneumonia Market

• 28.1. Middle East Bacterial Pneumonia Market Overview
• 28.2. Middle East Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bacterial Pneumonia Market

• 29.1. Africa Bacterial Pneumonia Market Overview
• 29.2. Africa Bacterial Pneumonia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bacterial Pneumonia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bacterial Pneumonia Market, Segmentation By Treatments, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bacterial Pneumonia Market Competitive Landscape And Company Profiles

• 30.1. Bacterial Pneumonia Market Competitive Landscape
• 30.2. Bacterial Pneumonia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Bacterial Pneumonia Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GSK plc
• 31.3. bioMerieux SA
• 31.4. Shionogi & Co. Ltd.
• 31.5. Wockhardt Limited.
• 31.6. Zai Lab Limited
• 31.7. Innoviva Inc.
• 31.8. Eagle Pharmaceuticals Inc.
• 31.9. Basilea Pharmaceutica Ltd.
• 31.10. Paratek Pharmaceuticals Inc.
• 31.11. Cumberland Pharmaceuticals Inc.
• 31.12. Melinta Therapeutics Inc.
• 31.13. Nabriva Therapeutics plc.
• 31.14. Clarametyx Biosciences Inc.
• 31.15. Evopoint Biosciences Inc.

32. Global Bacterial Pneumonia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bacterial Pneumonia Market

34. Recent Developments In The Bacterial Pneumonia Market

35. Bacterial Pneumonia Market High Potential Countries, Segments and Strategies

• 35.1 Bacterial Pneumonia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bacterial Pneumonia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bacterial Pneumonia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer